Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study

Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life

(2013) Jie Luo et al.   International Journal of Medical Sciences

Long-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus–Related Cirrhosis

(2012) Seyfettin Köklü et al.   Clinical Gastroenterology and Hepatology

Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients

(2012) María Buti et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice

(2012) Anne Liu et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901

(2012) Michael P Manns et al.   Expert Opinion On Drug Safety

Effectiveness of Hepatitis B Treatment in Clinical Practice

(2012) Steven J. Scaglione et al.   GASTROENTEROLOGY

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis

(2012) Roeland Zoutendijk et al.   GUT

Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir

(2012) Chia-Chi Wang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients

(2012) Atsushi Ono et al.   JOURNAL OF HEPATOLOGY

First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice

(2012) S. Pol et al.   JOURNAL OF VIRAL HEPATITIS

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

(2011) Man-Fung Yuen et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study

(2011) Yun-Fan Liaw et al.   HEPATOLOGY

Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice

(2011) E. Ridruejo et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B

(2010) Ting-Tsung Chang et al.   HEPATOLOGY

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease

(2010) Yun-Fan Liaw et al.   HEPATOLOGY

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

(2009) Christian M. Lange et al.   HEPATOLOGY

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

(2009) Daniel J. Tenney et al.   HEPATOLOGY

Chronic hepatitis B: Update 2009

(2009) Anna S. F. Lok et al.   HEPATOLOGY

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy

(2008) Daniel Shouval et al.   JOURNAL OF HEPATOLOGY